Medicare Enrolled
Dr. Don Wynn, M.D.
Pulmonary Disease · Denison, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Wynn from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wynn?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wynn
Dr. Don Wynn is a pulmonary disease specialist in Denison, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Wynn performed 40,514 Medicare services across 4,711 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wynn received a total of $27,019 from 46 pharmaceutical and/or device companies across 971 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wynn is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 0% volume in TX
$27,019 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,514
Medicare services
Top 0% in TX for pulmonary disease
4,711
Unique beneficiaries
$34
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,251 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Omalizumab injection (Xolair) for asthma/allergy | 27,917 | $30 | $55 |
| Allergy skin test A diagnostic test performed to identify specific allergies by applying or introducing allergenic extracts to the body. The procedure measures the patient's immune response to various potential allergens. |
1,976 | $3 | $9 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,177 | $88 | $158 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
1,047 | $24 | $43 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
1,026 | $52 | $107 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
804 | $0 | $2 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
688 | $91 | $146 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
587 | $125 | $219 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
526 | $59 | $101 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
415 | $0 | $1 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
408 | $39 | $85 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
406 | $42 | $77 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
328 | $19 | $49 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
270 | $27 | $75 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
245 | $25 | $56 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
199 | $11 | $33 |
| Injection, levofloxacin, 250 mg | 189 | $1 | $5 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
181 | $46 | $89 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
181 | $10 | $34 |
| Influenza virus detection test A laboratory test that uses an immunoassay technique to detect the presence of the influenza virus through direct visual observation. |
168 | $16 | $39 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
152 | $161 | $532 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
144 | $123 | $260 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
137 | $4 | $12 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
108 | $87 | $485 |
| Inhalation treatment for acute airway obstruction, first hour This procedure involves administering inhaled medication to treat acute airway obstruction during the first hour of treatment. |
107 | $43 | $61 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
100 | $15 | $51 |
| Injection, ciprofloxacin for intravenous infusion, 200 mg | 95 | $1 | $3 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
93 | $50 | $73 |
| Albuterol inhalation solution, 1 mg A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation. |
93 | $0 | $2 |
| Respiratory syncytial virus (RSV) nucleic acid test A laboratory test that uses nucleic acid amplification to detect the presence of respiratory syncytial virus in a sample. |
91 | $45 | $47 |
| New patient office visit, complex (60-74 min) | 89 | $151 | $269 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
78 | $81 | $422 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
70 | $11 | $38 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing, airflow, and physical effort during sleep. |
68 | $32 | $113 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
60 | $63 | $124 |
| Ultrasound scan of chest An imaging test that uses sound waves to create pictures of the structures inside the chest. |
56 | $43 | $102 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
53 | $5 | $5 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
49 | $83 | $329 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
44 | $28 | $50 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
36 | $22 | $56 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $128 | $247 |
| Chest fluid aspiration with imaging guidance This procedure involves removing fluid from the chest cavity using imaging technology to guide the needle placement. |
15 | $88 | $744 |
| Bronchoscopy A procedure to examine the airways inside the lungs using a thin, flexible tube with a camera. |
12 | $62 | $346 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
77.1% medium
21.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,019
Total received (2018-2024)
Avg $3,860/year across 7 years
Top 10% in TX for pulmonary disease
46
Companies
971
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,612 (61.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$10,407 (38.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$111
2023
$12,045
2022
$3,081
2021
$3,294
2020
$2,139
2019
$2,915
2018
$3,434
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Intuitive Surgical, Inc.
$11,269
GlaxoSmithKline, LLC.
$2,680
AstraZeneca Pharmaceuticals LP
$1,957
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,721
Mylan Specialty L.P.
$1,171
Actelion Pharmaceuticals US, Inc.
$854
Genentech USA, Inc.
$811
Pulmonx Corporation
$768
Novartis Pharmaceuticals Corporation
$618
GENZYME CORPORATION
$487
Sunovion Pharmaceuticals Inc.
$468
Grifols USA, LLC
$453
Teva Pharmaceuticals USA, Inc.
$433
United Therapeutics Corporation
$395
Regeneron Healthcare Solutions, Inc.
$341
Gilead Sciences, Inc.
$274
Takeda Pharmaceuticals U.S.A., Inc.
$256
Insmed, Inc.
$210
Philips Electronics North America Corporation
$195
Bayer HealthCare Pharmaceuticals Inc.
$182
Janssen Pharmaceuticals, Inc
$175
Mallinckrodt Hospital Products Inc.
$163
Mallinckrodt Enterprises LLC
$155
Amgen Inc.
$146
Mallinckrodt LLC
$105
Shire North American Group Inc
$100
Medtronic, Inc.
$89
Baxter Healthcare
$79
Advanced Respiratory, Inc
$67
AbbVie Inc.
$53
ANI Pharmaceuticals, Inc.
$47
ABIOMED
$40
Harmony Biosciences LLC
$32
ZOLL Respicardia, Inc.
$24
Exeltis, USA Inc.
$24
JAZZ PHARMACEUTICALS INC.
$23
ALK-Abello, Inc
$20
Merck Sharp & Dohme LLC
$17
Cumberland Pharmaceuticals, Inc.
$16
Covis Pharma GmBH
$16
Inogen, Inc.
$15
ABBVIE INC.
$15
Merck Sharp & Dohme Corporation
$15
ADVANCED RESPIRATORY, INC
$14
PFIZER INC.
$14
Circassia Pharmaceuticals Inc
$14
Top 3 companies account for 58.9% of total payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · ANORO · ANORO ELLIPTA · ASMANEX · AVYCAZ · Adempas · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHARTIS CATHETER · CINQAIR · CUVITRU · DUPIXENT · Da Vinci Surgical System · Esbriet · FASENRA · GLASSIA · Grastek · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · INPEN SMART INSULIN DELIVERY SYSTEM · ION · Impella · InogenOne · LONHALA MAGNAIR · Letairis · Life 2000 Ventilation System · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PANZYGA · PURIFIED CORTROPHIN GEL · Perforomist · ProAir Digihaler · Prolastin-C Liquid · REMODULIN · Respiratoriy Care Undiv · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · TECENTRIQ · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · UPTRAVI · UTIBRON · UTIBRON NEOHALER · Utibron · Veklury · Vibativ · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · Xembify · Xolair · YUPELRI · Yupelri · inCourage · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (62%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for pulmonary disease in TX.
Equivalent to $67 per 100 Medicare services performed
Geographic Context
Pulmonary diseases within 10 mi
4
Per 100K population
2.9
County median income
$70,455
Nearest hospital
TEXOMA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Wynn is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), with low-engagement industry engagement in the top 10% of TX peers, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Wynn experienced with omalizumab injection (xolair) for asthma/allergy?
Based on Medicare claims data, Dr. Wynn performed 27,917 omalizumab injection (xolair) for asthma/allergy services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wynn receive payments from pharmaceutical companies?
Yes. Dr. Wynn received a total of $27,019 from 46 companies across 971 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wynn's costs compare to other pulmonary diseases in Denison?
Dr. Wynn's average Medicare payment per service is $34. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wynn) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Denison
Browse pulmonary diseases in Denison ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
Intuitive Surgical, Inc. Payments to Doctors
See all physicians who received payments from Intuitive Surgical, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology